Table 1 Correlation between hsa-miR-378c expression and clinicopathologic characteristics of gastric cancer patients
From: NORAD-sponged miR-378c alleviates malignant behaviors of stomach adenocarcinoma via targeting NRP1
Characteristic | Low expression of hsa-miR-378c | High expression of hsa-miR-378c | p |
|---|---|---|---|
n | 223 | 223 | |
T stage, n (%) | 0.009 | ||
T1 | 6 (1.4%) | 17 (3.9%) | |
T2 | 51 (11.7%) | 41 (9.4%) | |
T3 | 111 (25.5%) | 88 (20.2%) | |
T4 | 52 (11.9%) | 70 (16.1%) | |
N stage, n (%) | 0.699 | ||
N0 | 60 (14.1%) | 71 (16.7%) | |
N1 | 62 (14.6%) | 57 (13.4%) | |
N2 | 44 (10.3%) | 43 (10.1%) | |
N3 | 47 (11%) | 42 (9.9%) | |
M stage, n (%) | 0.570 | ||
M0 | 195 (46%) | 199 (46.9%) | |
M1 | 17 (4%) | 13 (3.1%) | |
Pathologic stage, n (%) | 0.665 | ||
Stage I | 25 (6%) | 33 (7.9%) | |
Stage II | 69 (16.5%) | 62 (14.8%) | |
Stage III | 96 (22.9%) | 91 (21.7%) | |
Stage IV | 22 (5.3%) | 21 (5%) | |
Primary therapy outcome, n (%) | 0.337 | ||
PD | 42 (11.2%) | 31 (8.3%) | |
SD | 10 (2.7%) | 8 (2.1%) | |
PR | 5 (1.3%) | 2 (0.5%) | |
CR | 133 (35.5%) | 144 (38.4%) | |
Gender, n (%) | 0.197 | ||
Female | 71 (15.9%) | 85 (19.1%) | |
Male | 152 (34.1%) | 138 (30.9%) | |
Race, n (%) | 0.662 | ||
Asian | 50 (13%) | 43 (11.2%) | |
Black or African American | 6 (1.6%) | 7 (1.8%) | |
White | 135 (35.2%) | 143 (37.2%) | |
Histological type, n (%) | 0.851 | ||
Diffuse Type | 36 (8.1%) | 36 (8.1%) | |
Mucinous Type | 13 (2.9%) | 9 (2%) | |
Not Otherwise Specified | 122 (27.5%) | 126 (28.4%) | |
Papillary Type | 6 (1.4%) | 3 (0.7%) | |
Signet Ring Type | 6 (1.4%) | 6 (1.4%) | |
Tubular Type | 38 (8.6%) | 42 (9.5%) | |
Residual tumor, n (%) | 0.450 | ||
R0 | 173 (44.6%) | 178 (45.9%) | |
R1 | 12 (3.1%) | 7 (1.8%) | |
R2 | 10 (2.6%) | 8 (2.1%) | |
Histologic grade, n (%) | 0.569 | ||
G1 | 6 (1.4%) | 4 (0.9%) | |
G2 | 75 (17.2%) | 85 (19.5%) | |
G3 | 137 (31.4%) | 130 (29.7%) | |
Anatomic neoplasm subdivision, n (%) | 0.239 | ||
Antrum/Distal | 80 (18.7%) | 83 (19.4%) | |
Cardia/Proximal | 39 (9.1%) | 25 (5.8%) | |
Fundus/Body | 76 (17.8%) | 75 (17.5%) | |
Gastroesophageal Junction | 19 (4.4%) | 27 (6.3%) | |
Other | 1 (0.2%) | 3 (0.7%) | |
Reflux history, n (%) | 0.022 | ||
No | 115 (44.7%) | 94 (36.6%) | |
Yes | 17 (6.6%) | 31 (12.1%) | |
Antireflux treatment, n (%) | 0.307 | ||
No | 94 (43.5%) | 79 (36.6%) | |
Yes | 19 (8.8%) | 24 (11.1%) | |
H pylori infection, n (%) | 0.089 | ||
No | 79 (42.7%) | 86 (46.5%) | |
Yes | 5 (2.7%) | 15 (8.1%) | |
Barretts esophagus, n (%) | 1.000 | ||
No | 110 (44.2%) | 121 (48.6%) | |
Yes | 9 (3.6%) | 9 (3.6%) | |
OS event, n (%) | 0.120 | ||
Alive | 128 (28.7%) | 145 (32.5%) | |
Dead | 95 (21.3%) | 78 (17.5%) | |
DSS event, n (%) | 0.021 | ||
Alive | 149 (35.6%) | 168 (40.1%) | |
Dead | 62 (14.8%) | 40 (9.5%) | |
PFI event, n (%) | 0.020 | ||
Alive | 139 (31.2%) | 163 (36.5%) | |
Dead | 84 (18.8%) | 60 (13.5%) | |
Age, meidan (IQR) | 66 (58, 72) | 68 (58, 74) | 0.231 |